Hyper-radiosensitivity affects low-dose acute myeloid leukemia incidence in a mathematical model.
Acute myeloid leukemia
CBA mice
Hyper-radiosensitivity
Ionizing radiation exposure
Low dose
Mathematical modeling
Journal
Radiation and environmental biophysics
ISSN: 1432-2099
Titre abrégé: Radiat Environ Biophys
Pays: Germany
ID NLM: 0415677
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
07
07
2021
accepted:
11
06
2022
pubmed:
22
7
2022
medline:
2
8
2022
entrez:
21
7
2022
Statut:
ppublish
Résumé
In vitro experiments show that the cells possibly responsible for radiation-induced acute myeloid leukemia (rAML) exhibit low-dose hyper-radiosensitivity (HRS). In these cells, HRS is responsible for excess cell killing at low doses. Besides the endpoint of cell killing, HRS has also been shown to stimulate the low-dose formation of chromosomal aberrations such as deletions. Although HRS has been investigated extensively, little is known about the possible effect of HRS on low-dose cancer risk. In CBA mice, rAML can largely be explained in terms of a radiation-induced Sfpi1 deletion and a point mutation in the remaining Sfpi1 gene copy. The aim of this paper is to present and quantify possible mechanisms through which HRS may influence low-dose rAML incidence in CBA mice. To accomplish this, a mechanistic rAML CBA mouse model was developed to study HRS-dependent AML onset after low-dose photon irradiation. The rAML incidence was computed under the assumptions that target cells: (1) do not exhibit HRS; (2) HRS only stimulates cell killing; or (3) HRS stimulates cell killing and the formation of the Sfpi1 deletion. In absence of HRS (control), the rAML dose-response curve can be approximated with a linear-quadratic function of the absorbed dose. Compared to the control, the assumption that HRS stimulates cell killing lowered the rAML incidence, whereas increased incidence was observed at low doses if HRS additionally stimulates the induction of the Sfpi1 deletion. In conclusion, cellular HRS affects the number of surviving pre-leukemic cells with an Sfpi1 deletion which, depending on the HRS assumption, directly translates to a lower/higher probability of developing rAML. Low-dose HRS may affect cancer risk in general by altering the probability that certain mutations occur/persist.
Identifiants
pubmed: 35864346
doi: 10.1007/s00411-022-00981-7
pii: 10.1007/s00411-022-00981-7
pmc: PMC9334435
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-373Informations de copyright
© 2022. The Author(s).
Références
Radiother Oncol. 2010 Jan;94(1):90-101
pubmed: 19931928
Radiat Environ Biophys. 2011 Mar;50(1):37-45
pubmed: 20842369
Br J Cancer. 1979 Dec;40(6):903-13
pubmed: 294292
Radiat Environ Biophys. 2021 Mar;60(1):49-60
pubmed: 33221961
Nature. 2014 Feb 20;506(7488):328-33
pubmed: 24522528
Carcinogenesis. 2020 Aug 12;41(8):1104-1112
pubmed: 31646336
Blood. 2004 Dec 1;104(12):3437-44
pubmed: 15304397
Am J Med. 1952 Sep;13(3):311-21
pubmed: 12985588
Genes Chromosomes Cancer. 1999 Feb;24(2):95-104
pubmed: 9885975
Phys Med Biol. 2018 Dec 19;64(1):01TR01
pubmed: 30523903
Leuk Res. 2013 Oct;37(10):1374-82
pubmed: 23806234
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):379-89
pubmed: 11173131
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6
pubmed: 14610281
Br J Cancer. 2009 Jul 21;101(2):363-71
pubmed: 19513063
Radiat Res. 1993 Jan;133(1):41-51
pubmed: 8434112
J Math Biol. 2018 Dec;77(6-7):1969-1997
pubmed: 29679122
Int J Radiat Biol. 1993 May;63(5):639-50
pubmed: 8099110
Mol Cell. 2013 Mar 7;49(5):934-46
pubmed: 23395001
Radiat Res. 2009 Apr;171(4):474-83
pubmed: 19397448
Nat Immunol. 2004 Jul;5(7):738-43
pubmed: 15170211
Radiat Res. 2011 Sep;176(3):311-22
pubmed: 21692655
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1486-91
pubmed: 16432184
Phys Med Biol. 2000 Feb;45(2):279-93
pubmed: 10701504
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):82-90
pubmed: 25442345
Int J Radiat Biol. 2001 Jun;77(6):655-64
pubmed: 11403705
Radiat Res. 2009 Sep;172(3):368-82
pubmed: 19708786
Risk Anal. 1988 Sep;8(3):383-92
pubmed: 3201016
J Math Biol. 2019 Oct;79(5):1831-1883
pubmed: 31410551
Risk Anal. 1989 Jun;9(2):179-87
pubmed: 2762604
Int J Radiat Biol. 2017 Oct;93(10):1009-1014
pubmed: 28151050
Int J Radiat Biol. 1999 Nov;75(11):1341-8
pubmed: 10597908
Phys Med Biol. 1973 Jan;18(1):78-87
pubmed: 4803965
Leuk Res. 1983;7(2):295-300
pubmed: 6574298
Nature. 1978 Mar 30;272(5652):455-6
pubmed: 273147
Oncogene. 2005 May 19;24(22):3678-83
pubmed: 15750630
Int J Radiat Biol. 1997 Aug;72(2):181-9
pubmed: 9269311
Radiat Res. 2013 Mar;179(3):361-82
pubmed: 23398354
Math Med Biol. 2013 Mar;30(1):1-19
pubmed: 22006625
Cancer Lett. 2013 Sep 28;338(2):209-18
pubmed: 23693079
Leukemia. 2018 Jun;32(6):1435-1444
pubmed: 29556020
Cell Rep. 2017 Sep 26;20(13):3199-3211
pubmed: 28954235
Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11842-9
pubmed: 14504387
Radiat Res. 1994 Feb;137(2 Suppl):S68-97
pubmed: 8127953
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1310-8
pubmed: 18374221
Int J Radiat Biol. 2021;97(1):2-11
pubmed: 32573309
Int J Radiat Biol. 2019 Jul;95(7):892-899
pubmed: 30652952
Leukemia. 2012 Jun;26(6):1445-6
pubmed: 22289922
Mutat Res. 2013 Aug 30;756(1-2):119-26
pubmed: 23665297
Radiat Environ Biophys. 2008 Jul;47(3):375-88
pubmed: 18481074
Radiat Res. 2002 Jul;158(1):43-53
pubmed: 12071802
Carcinogenesis. 2015 Apr;36(4):413-9
pubmed: 25750172
Blood. 2005 Dec 15;106(13):4086-92
pubmed: 16131573
J Radiol Prot. 2019 Jul 11;39(4):S1-S13
pubmed: 31292290
Cell Stem Cell. 2010 Aug 6;7(2):174-85
pubmed: 20619762
Br J Cancer. 1983 Feb;47(2):285-91
pubmed: 6337614